Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor

Izrael - angličtina - Ministry of Health

inovamed pharma ltd, israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor inovamed , co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event. limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Izrael - angličtina - Ministry of Health

teva israel ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event . limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Saudská Arábia - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - ticagrelor - film-coated tablet - 90 mg,

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor s.k., co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Izrael - angličtina - Ministry of Health

propharm ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor propharm is indicated for co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Izrael - angličtina - Ministry of Health

novartis israel ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor sandoz®, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - ticagrelor -